Oak Ridge National Laboratory has activated Pathfinder, a 20‑qubit IQM Radiance quantum computer — the lab’s first purchased system — to explore hybrid quantum‑HPC research.

A Rutgers genetic survey found many city mice carry mutations that blunt commonly used poisons, complicating pest control in Brooklyn.

A Parkfield study using machine learning found short slow‑slip events that boost low‑frequency quakes, prompting scientists to rethink how California's hazard models account for transient stress.

Riley Hospital at IU Health used cryopreserved marrow from a deceased donor in a world‑first pediatric transplant, putting a 14‑year‑old with leukemia into remission.

A proposed class‑action alleges Anthropic misled customers about token allowances on its $100 and $200 Claude Max plans and seeks refunds and class certification.

Penn’s ApexGO uses generative AI to refine peptide antibiotics; 85% of synthesized designs killed bacteria in lab tests and some matched last‑resort drugs in mice.

Lunar Resources plans a HELIX‑1 pulsed‑power factory in Salt Lake County, projected to create 420 jobs and bring nearly $48 million in new state tax revenue over 10 years.

A class-action suit alleges St. Louis health giant Ascension shared private patient records with Google, claiming violations of federal privacy rules and seeking class relief.

Cincinnati Childrens won a five‑year, up‑to‑$17.25M ARIA award to join the IMPACT Network and begin local enrollment for a study meant to speed autism trials.

Microsoft CEO Satya Nadella warned that a handful of dominant AI systems could “hollow out entire industries,” urging firms to build private learning loops to protect jobs and IP.

A multilayered security buildout uses AI cameras and counter‑drone gear to guard matches and fan zones in Miami. Officials say the tech flags threats in real time while agencies enforce no‑drone rules.

UH Mānoa researchers published the first live, in‑situ footage of goblin sharks, documenting Central Pacific sightings that extend the species’ depth and range.

Pitt researchers turned a harmless eye bacterium into a prototype "living eye drop" that secretes anti-inflammatory IL-10 and sped cornea healing in mice. The proof-of-concept could reduce repeated dosing, but human trials are still distant.